CIBC Asset Management Inc Boosts Holdings in Becton, Dickinson and Company (NYSE:BDX)

CIBC Asset Management Inc lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,923 shares of the medical instruments supplier’s stock after purchasing an additional 2,824 shares during the period. CIBC Asset Management Inc’s holdings in Becton, Dickinson and Company were worth $13,717,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BDX. PineStone Asset Management Inc. lifted its position in shares of Becton, Dickinson and Company by 141.6% in the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after acquiring an additional 788,735 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in Becton, Dickinson and Company by 32.5% during the 2nd quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after purchasing an additional 688,296 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Becton, Dickinson and Company by 8.5% during the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after buying an additional 346,720 shares in the last quarter. Magnetar Financial LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $75,493,000. Finally, Ameriprise Financial Inc. boosted its position in Becton, Dickinson and Company by 6.4% during the second quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock worth $1,181,483,000 after acquiring an additional 302,893 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Down 0.9 %

Becton, Dickinson and Company stock opened at $225.15 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The firm has a 50 day moving average price of $236.30 and a 200 day moving average price of $234.99. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $249.89. The company has a market capitalization of $65.08 billion, a PE ratio of 37.90, a price-to-earnings-growth ratio of 1.72 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the business earned $3.42 EPS. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be paid a $1.04 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. This represents a $4.16 annualized dividend and a dividend yield of 1.85%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 70.03%.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of research reports. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Raymond James reduced their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.